VKTX stock icon

Viking Therapeutics

65.84 USD
+3.39
5.43%
At close Oct 11, 4:00 PM EDT
After hours
65.60
-0.24
0.36%
1 day
5.43%
5 days
0.35%
1 month
8.24%
3 months
12.30%
6 months
-7.10%
Year to date
260.18%
1 year
503.48%
5 years
928.75%
 

About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Employees: 30

0
Funds holding %
of 6,740 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

104% more call options, than puts

Call options by funds: $321M | Put options by funds: $157M

60% more repeat investments, than reductions

Existing positions increased: 162 | Existing positions reduced: 101

24% more first-time investments, than exits

New positions opened: 93 | Existing positions closed: 75

5% more funds holding

Funds holding: 366 [Q1] → 384 (+18) [Q2]

1.08% less ownership

Funds ownership: 73.93% [Q1] → 72.85% (-1.08%) [Q2]

36% less capital invested

Capital invested by funds: $6.63B [Q1] → $4.26B (-$2.37B) [Q2]

54% less funds holding in top 10

Funds holding in top 10: 13 [Q1] → 6 (-7) [Q2]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$80
22%
upside
Avg. target
$104
57%
upside
High target
$138
110%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Joseph Pantginis
35% 1-year accuracy
90 / 255 met price target
37%upside
$90
Buy
Reiterated
9 Oct 2024
Oppenheimer
Jay Olson
29% 1-year accuracy
14 / 48 met price target
110%upside
$138
Outperform
Reiterated
25 Sept 2024
Morgan Stanley
Michael Ulz
41% 1-year accuracy
7 / 17 met price target
59%upside
$105
Overweight
Reiterated
12 Sept 2024
JP Morgan
Hardik Parikh
50% 1-year accuracy
2 / 4 met price target
22%upside
$80
Overweight
Initiated
11 Sept 2024
Raymond James
Steven Seedhouse
50% 1-year accuracy
11 / 22 met price target
79%upside
$118
Strong Buy
Maintained
25 Jul 2024

Financial journalist opinion

Based on 25 articles about VKTX published over the past 30 days

Charts implemented using Lightweight Charts™